RhumbLine Advisers’s MapLight Therapeutics MPLT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$144K Sell
14,156
-1,592
-10% -$29.9K ﹤0.01% 3402
2026
Q2
$564K Sell
15,748
-4,620
-23% -$133K ﹤0.01% 2685
2026
Q1
$414K Buy
20,368
+6,726
+49% +$120K ﹤0.01% 2724
2025
Q4
$240K Buy
+13,642
New +$229K ﹤0.01% 3091

Other funds holding MPLT

RhumbLine Advisers's MPLT Position: Q3 2026 in Review

RhumbLine Advisers reduced its MapLight Therapeutics (MPLT) stake by 10% in Q3 2026, selling an estimated $29.9K and leaving 14,156 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #3402.

RhumbLine Advisers first reported a position in MPLT in Q4 2025 and has held it in 4 quarters since. The position peaked at $564K in Q2 2026. 98 funds tracked by Wall St. Rank hold MPLT as of Q3 2026.

  • RhumbLine Advisers held 14,156 shares of MapLight Therapeutics worth $144K as of Q3 2026.
  • RhumbLine Advisers sold 1,592 MapLight Therapeutics shares in Q3 2026, an estimated $29.9K.
  • MapLight Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3402 holding.
  • RhumbLine Advisers first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • RhumbLine Advisers's MapLight Therapeutics position peaked at $564K in Q2 2026.
  • 98 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.